Clinical and Translational Radiation Oncology最新文献

{"title":"Vestibular dose predicts toxicity in stereotactic radiosurgery for vestibular schwannomas","authors":"Dimitrios Daskalou ,&nbsp;Edouard Romano ,&nbsp;Sophie Neveü ,&nbsp;Pelagia Tsoutsou ,&nbsp;Nikolaos Koutsouvelis ,&nbsp;Francis Rousset ,&nbsp;Nils Guinand ,&nbsp;Minerva Becker ,&nbsp;Pascal Senn ,&nbsp;Sebastien Tran","doi":"10.1016/j.ctro.2025.101105","DOIUrl":"10.1016/j.ctro.2025.101105","url":null,"abstract":"<div><h3>Introduction</h3><div>Stereotactic radiosurgery (SRS) provides excellent tumor control in small and medium vestibular schwannomas (VS), but its impact on the vestibular system remains uncertain. This study examines the effects of SRS on subjective vestibular symptoms, vestibular function, and potential predictors of symptom worsening.</div></div><div><h3>Materials and methods</h3><div>A retrospective analysis was conducted on adult VS patients treated with SRS over eight years. Vestibular symptoms were graded at baseline and six months post-SRS. The vestibular sensory organs (VSO) were defined as the combined volume of the saccule, utricle, and ampullae. Vestibular function was assessed with bithermal, bilateral caloric testing, video head impulse testing, and vestibular evoked myogenic potentials. Two illustrative treatment plans were generated to assess feasibility of vestibular dose reduction without compromising planning target volume (PTV) or cochlear constraints.</div></div><div><h3>Results</h3><div>Among 45 VS patients (median age 61.4 years), 14 (31 %) reported worsened vestibular symptoms at six months. These patients had higher Dose_mean to VSO (6.45 Gy vs 2.92 Gy, p &lt; 0.0001). A Dose_mean &gt; 4 Gy was strongly associated with symptom worsening (OR = 27.3, 95 % CI [3.4–301.8], p = 0.0002). Similar associations were observed for Dose_max, with an 8 Gy threshold. Higher Dose_mean to the lateral ampulla was correlated with a greater percentage change in caloric weakness (slope = 7.77, R² = 0.38, p = 0.04). In two illustrative plans, VSO optimisation lowered vestibular dose without compromising PTV coverage or cochlear dose.</div></div><div><h3>Conclusion</h3><div>Higher vestibular radiation dose is strongly associated with worsened vestibular symptoms and possibly with functional decline. Dose reduction to vestibular subunits is feasible without compromising the tumor dose, helping mitigate these effects.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101105"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharyngeal mucositis and esophagitis after re-irradiation spine stereotactic body radiotherapy with 24 Gy in two fractions","authors":"Kei Ito ,&nbsp;Kentaro Taguchi ,&nbsp;Yujiro Nakajima ,&nbsp;Keiko Nemoto Murofushi","doi":"10.1016/j.ctro.2025.101100","DOIUrl":"10.1016/j.ctro.2025.101100","url":null,"abstract":"<div><h3>Background</h3><div>Pharyngeal mucositis and esophagitis incidence following re-irradiation stereotactic body radiotherapy (SBRT) for spinal metastases remains unclear. We retrospectively examined their incidence and risk factors after re-irradiation SBRT to clarify organ tolerance.</div></div><div><h3>Methods and materials</h3><div>Patients who underwent spine SBRT following prior conventional radiotherapy were included if the SBRT delivered more than 10 Gy to the pharynx or esophagus. SBRT dose was limited to 24 Gy in two fractions. Dose constraints were pharyngeal D_{1 cc} &lt; 20, esophageal D_{2.5 cc} &lt; 19, and D_{0.035 cc} &lt; 24 Gy. The primary endpoint was pharyngeal mucositis and esophagitis occurrence. Patient demographics, clinical factors, and dose-volume parameters were analyzed as predictors of symptomatic toxicities.</div></div><div><h3>Results</h3><div>Ninety-three patients were included (60 males; median age, 66 years). The median follow-up was 15 (range: 3–111) months. One patient with grade 3 toxicity (1 %) was observed, with no grade 4–5 toxicities. Grade 1 (symptomatic) pharyngeal mucositis occurred in 58 % (14/24) of patients, and grade 2 esophagitis occurred in 27 % (23/85). Clinical factors and symptomatic toxicities were not significantly associated. The estimated D_max values corresponding to a 20 % risk of symptomatic toxicity were 16.6 Gy for the pharynx and 22.8 Gy for the esophagus.</div></div><div><h3>Conclusions</h3><div>Grade ≥ 3 pharyngeal mucositis and esophagitis were rare; the current dose constraints are safe for re-irradiated spine SBRT. Reducing the pharyngeal and esophageal maximum doses may be helpful among patients for whom avoiding symptomatic mucositis is particularly important.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101100"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145837694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetric comparison between brachytherapy and MR-Linac as a boost modality for locally advanced cervical cancer","authors":"Renske van Noortwijk,&nbsp;Petra S. Kroon,&nbsp;Katelijne M. van Vliet-van den Ende,&nbsp;Erik H. Brondijk,&nbsp;Gonda G. Sikkes,&nbsp;Alexis N.T.J. Kotte,&nbsp;Ina M. Jürgenliemk-Schulz,&nbsp;Femke van der Leij,&nbsp;Astrid L.H.M.W. van Lier","doi":"10.1016/j.ctro.2025.101098","DOIUrl":"10.1016/j.ctro.2025.101098","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Standard treatment for locally advanced cervical cancer (LACC) is chemoradiotherapy followed by a brachytherapy (BT) boost. However, BT is not always feasible and magnetic resonance (MR)-guided adaptive radiotherapy on the MR-Linac (MRL) might be an alternative. To investigate the dosimetric feasibility of MRL, BT and MRL treatment plans were compared intra-patient in terms of dosimetric differences, next to anatomical and conformity variations.</div></div><div><h3>Materials and methods</h3><div>Two groups of ten patients with LACC treated with BT boost were selected: group 1 included patients for which at least one clinically established (EMBRACE II) treatment planning constraint was not achieved during BT, in group 2 all planning constraints were achieved.</div><div>BT treatment plans were compared with MRL treatment plans (based on MRI scans without applicator in place) intra-patient, in terms of dose-volume histogram (DVH) parameters, target-to-OAR (organ at risk) surface distances and conformity ratios.</div></div><div><h3>Results</h3><div>Group 1 resulted in similar prescribed target dose levels for MRL compared to BT, for group 2 all prescribed target dose levels were significantly higher for BT. Rectum D2cm³ was higher for all MRL treatment plans. Volumes of higher dose levels were larger for BT, volumes of lower dose levels were larger for MRL and the CTV_HR to OAR (rectum, sigmoid, bowel) surface distance was greater for BT.</div></div><div><h3>Conclusion</h3><div>This retrospective study demonstrates that with an MRL boost plan, in some situations it is possible to achieve established planning constraints. However, as rectum doses are higher and dose distributions are fundamentally different, BT remains the modality of choice. Clinical trials are necessary to investigate the influence of the MRL dose distribution on oncological outcomes.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101098"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145798322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benefit of prophylactic pelvic irradiation in intermediate-risk prostate cancer: A multicenter retrospective study (iPPAPI)","authors":"Charles Raynaud ,&nbsp;Rafik Nebbache ,&nbsp;Yazid Belkacemi ,&nbsp;Cyrus Chargari ,&nbsp;Catherine Durdux ,&nbsp;Christophe Hennequin ,&nbsp;Florence Huguet ,&nbsp;Laurent Quero ,&nbsp;Jean-Emmanuel Bibault","doi":"10.1016/j.ctro.2025.101093","DOIUrl":"10.1016/j.ctro.2025.101093","url":null,"abstract":"<div><div>Context.</div><div>Prostate cancer (PCa) is the most common urologic malignancy in men, with most cases diagnosed at a localized stage. The benefit of whole-pelvic radiotherapy (WPRT) to eradicate subclinical nodal disease remains debated, particularly in intermediate-risk PCa. This study assessed the impact of WPRT in this population.</div></div><div><h3>Methods</h3><div>We conducted a multicenter retrospective study within the AP-HP GRRAP program across five radiotherapy departments. Biopsy-proven intermediate-risk PCa (d’Amico classification) treated with conformational external beam radiotherapy between 2010 and 2019 were included. The primary endpoint was recurrence-free survival (RFS), defined as time from diagnosis to biochemical, local, metastatic recurrence, or death. Secondary endpoints were overall survival (OS) and acute (&lt;6 months) or late (≥6 months) genitourinary (GU), gastrointestinal (GI), and sexual toxicities (CTCAE v4.03/v5.0). Survival outcomes were assessed using univariate and multivariate Cox models.</div></div><div><h3>Results</h3><div>Three hundred patients (60 per center) were included; 94 % received IMRT and 6 % 3D-RT. After a median follow-up of 77 months, univariate analysis showed no significant association between WPRT and RFS (HR; 0.61; 95 % CI, 0.26–1.42; p = 0.25). Multivariable analysis adjusted for clinical and treatment factors yielded similar results (HR, 0.70; 95 % CI, 0.27 to 1.81; <em>p</em> = 0.46). OS results were also comparable. Rates of grade 2 acute or late toxicities were similar, but grade ≥ 3 late GI toxicity was higher with WPRT (14.3 % vs. 5.4 %; p = 0.045; OR 2.90).</div></div><div><h3>Conclusion</h3><div>In intermediate-risk PCa, WPRT did not improve RFS or OS compared with prostate-only RT but was associated with an increased risk of severe GI toxicity.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101093"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145697912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pan-Cancer profiling of ferroptosis-related genes reveals prognostic biomarkers and sex-specific associations","authors":"Max Samuel,&nbsp;Laure Marignol","doi":"10.1016/j.ctro.2025.101095","DOIUrl":"10.1016/j.ctro.2025.101095","url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate the association of ferroptosis-related gene expression with overall survival (OS) across multiple cancer types and explore their relationship to biological sex and radiation therapy (RT) outcomes.</div></div><div><h3>Methods</h3><div>Ferroptosis regulators were identified through a literature review and cross-referenced with the FerrDb database, yielding 55 candidate genes. Five cancers commonly treated with RT were selected. Kaplan-Meier analyses were performed to assess OS associations for each gene, with hazard ratios (HR) and p-values recorded. Segregated analysis according to biological sex were conducted on candidate genes. The analysis was repeated in a cohort of RT treated lung cancer patients.</div></div><div><h3>Results</h3><div>Across five cancers commonly treated with radiation therapy (RT), 18–35 of 55 ferroptosis-related genes were significantly associated with overall survival (OS). <em>GLS2</em> and <em>BECN1</em> were significantly associated with improved OS in all five cancers. <em>SLC7A11</em> was significant in four cancers and generally associated with poorer OS. Sex differences in the association between these three genes and OS were detected. In RT-treated lung cancer patients (n = 65), <em>HSPB1</em>, <em>GLS2</em> and <em>GPX4</em> were associated with improved OS, <em>SLC7A11</em> with worse OS.</div></div><div><h3>Conclusions</h3><div>This study provides first evidence of sex-differences in ferroptosis-related gene expression with potential clinical relevance. This pan-cancer resource links ferroptosis-related genes to survival outcomes and highlights <em>SLC7A11</em>, <em>BECN1</em>, and <em>GLS2</em> as high-priority candidates for future mechanistic and clinical studies. Integrating sex as a biological variable into study design and interpretation will enhance clinical relevance.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101095"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145798240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemoradiation of glioblastoma cells alters expression of activation and immune checkpoint molecules on type 1 and 2 dendritic cells and impacts on subsequent T cell proliferation","authors":"Celina Schuster ,&nbsp;Benjamin Frey ,&nbsp;Rainer Fietkau ,&nbsp;Stefanie Corradini ,&nbsp;Udo S. Gaipl ,&nbsp;Anja Derer","doi":"10.1016/j.ctro.2025.101102","DOIUrl":"10.1016/j.ctro.2025.101102","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Glioblastoma is the most aggressive malignant brain tumor with an overall poor prognosis despite advanced chemoradiation approaches. Immunotherapeutic strategies have not been beneficial to date. Even being present only at low level in the brain, dendritic cells (DCs) have the potential to promote anti-tumor immune responses. In this study we aimed to gain insight into the interactions between glioblastoma tumor cells, DCs and T cells to understand the molecular and cellular mechanisms driving immune alterations in glioblastoma during standard treatments for optimizing immune therapies in the future.</div></div><div><h3>Material and methods</h3><div>Impact of the conventional chemoradiation (RCT) treatment scheme of glioblastoma cells on conventional DCs type 1 and 2 (cDC) was tested in a syngeneic murine cell culture setting. GL261-luc2 glioblastoma cells were treated and subsequently co-cultured with cDC1-like and cDC2-like cells. Their immunological status was determined as follows: Expression of activation and immune checkpoint markers was quantified via flow cytometry. Cytokine and chemokine secretion was measured by bead-based immunoassays. Mixed lymphocyte reactions with either CD4+ or CD8+ T cells were performed to determine the potential of cDCs in stimulating T cell proliferation.</div></div><div><h3>Results</h3><div>The cellular contact of cDC1-like cells with RCT-treated glioblastoma cells shifted their immune phenotype to a more activated one, whereas the activation of cDC2-like cells was limited. Furthermore, the extracellular profile of inflammatory and immunoregulatory cytokines and chemokines was highly dependent on the tumor cell treatment scheme in co-culture with cDC1-like cells, with the most pronounced effect after RCT. These modifications in the activation status of cDC1- and cDC2-like cells after tumor cell contact subsequently resulted in significantly enhanced CD8⁺ and CD4⁺ T cell proliferation.</div></div><div><h3>Conclusion</h3><div>Current glioblastoma cell treatment impacts on the subsequent activation of cDCs and T cells and should serve as basis for improving immunotherapeutic strategies of brain tumors.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101102"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146034771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective evaluation of liver cancer volumes on non-contrast 1.5 T MR Linac imaging","authors":"Aisling M. Glynn ,&nbsp;Saheli Saha ,&nbsp;Ian J. Gerard ,&nbsp;Michael Velec ,&nbsp;Teodor Stanescu ,&nbsp;Juan Diaz Martinez ,&nbsp;Pablo Munoz-Schuffenegger ,&nbsp;Ali Hosni ,&nbsp;Aruz Mesci ,&nbsp;Michael Yan ,&nbsp;Cathy Rocca ,&nbsp;Andrea Shessel ,&nbsp;Tae Kyoung Kim ,&nbsp;Laura A. Dawson","doi":"10.1016/j.ctro.2026.101110","DOIUrl":"10.1016/j.ctro.2026.101110","url":null,"abstract":"<div><h3>Background</h3><div>The 1.5 T MR-Linac (MRL) provides a platform for online adaptive stereotactic body radiation therapy (SBRT). This study aims to compare gross tumor volume (GTV) on multiphasic (MP) CT and MR simulation imaging versus non-contrast MRL images and to measure changes in GTV during SBRT.</div></div><div><h3>Methods</h3><div>Primary or metastatic liver cancer patients treated with SBRT using MRL or cone beam CT (CBCT) were eligible for this prospective imaging study. At simulation, patients underwent MP CT and MP 3 T MR liver T1-weighted (T1w) imaging in exhale breath hold and T2-weighted (T2w) images on 1.5 T MRL (MRL0). Repeat MRL T2w images were acquired at each SBRT fraction. Liver tumors were contoured on simulation CT/MR and MRL0 images and on each subsequent MRL image. MRL0 GTV were compared to MP CT/MR GTV and changes during SBRT were measured.</div></div><div><h3>Results</h3><div>From August 2019 to January 2023, 29 liver tumors (23 patients) treated with SBRT, were contoured on 23 MP CT/3T MR and 103 MRL imaging datasets. Simulation MRL0 interquartile median GTV was 43.3 cc (IQR 4.3–47.7 cc), GTV on MRL0 images were smaller than MP CT/3T MR volumes by an average of 7.1 cc (95 % CI 1.9–12.2, p = 0.008) or 21.9 % (95 % CI 13.5–30.2, p = &lt;0.001). Over the course of SBRT there were no statistically significant predictable trends in tumor volume.</div></div><div><h3>Conclusion</h3><div>GTV based on MRL T2w images were significantly smaller than GTV based on MP CT/3T MR images. This systematic difference should be considered during adaptive MRL liver SBRT. There were no predictable changes in tumor volumes during SBRT.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101110"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146034770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cumulative oesophageal dose and risk of high-grade toxicity in thoracic re-irradiation: a dose/toxicity analysis","authors":"Robert Rulach ,&nbsp;Stephen Harrow ,&nbsp;Anthony J. Chalmers ,&nbsp;John Fenwick","doi":"10.1016/j.ctro.2026.101108","DOIUrl":"10.1016/j.ctro.2026.101108","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Re-irradiation (re-RT) in recurrent thoracic cancer is being performed more often and can cause severe toxicity. Information is lacking on safe re-irradiation dose constraints. We modelled the relationship between cumulative oesophageal dose and grade 3 or worse (≥G3) oesophageal toxicity to develop<!--> <!-->dose constraints.</div></div><div><h3>Materials and methods</h3><div>We performed a literature search for reports of thoracic re-RT and selected studies that quoted cumulative oesophageal maximum dose (cD_max) in equivalent dose in 2 Gy fractions (EQD2) and ≥G3 toxicity. Additional collected data were<!--> <!-->inter-treatment interval and concurrent chemotherapy use (conCT) at re-irradiation. Logistic regression analyses were performed. The models were used to predict the cD_max <!-->associated with a 5%<!--> <!-->≥G3 toxicity rate. Model performance was assessed using the Pearson correlation coefficient (PCC).</div></div><div><h3>Results</h3><div>We identified 21 studies (505 patients), with 49 ≥G3 toxic events. The median oesophageal cD_max <!-->and interval were 84.8 Gy₃ <!-->(3.7 – 220.6 Gy₃ <!-->EQD2) and 15.5 months (1–162) respectively. Use of conCT and oesophageal cD_max <!-->were significantly associated with toxicity on univariable and multivariable modelling (both p &lt; 0.001). The maximum likelihood doses associated with 5% risk of ≥G3 toxicity with/without chemotherapy were cD_max <!-->43.0 Gy₃ <!-->(95% CI: −18.5, 108.8) and 94.2 Gy₃ <!-->(95% CI: 79.6, 142.8) respectively. The model had a PCC of 0.75 (p = 0.013) suggesting good correlation to the dataset.</div></div><div><h3>Conclusion</h3><div>The models predict a 5% toxicity<!--> <!-->at cD_max <!-->43.0 Gy₃ <!-->and 94.2 Gy₃ <!-->EQD2 with/without chemotherapy. This<!--> <!-->supports a cD_max <!-->constraint of &lt;95 Gy₃ <!-->EQD2 to limit ≥G3 toxicity to under 5%,<!--> <!-->consistent with the<!--> <!-->American Radium Society constraints (&lt;100 Gy₃ <!-->EQD2). ConCT with re-irradiation has a large radiosensitising effect.<!--> <!-->Limitations of this study include the use of old, retrospective data resulting in<!--> <!-->wide CIs around the<!--> <!-->predictions and insufficient data to<!--> <!-->predict a volumetric constraint. Further modelling with more detailed dose data is required to refine and validate these predictions.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101108"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal conservative local treatment based on combined brachytherapy and external beam radiation therapy for paediatric pelvic and perineal rhabdomyosarcoma","authors":"Xavier Musset ,&nbsp;Sophie Espenel ,&nbsp;Jeanne Riverain ,&nbsp;Elaine Limkin ,&nbsp;Florent Guerin ,&nbsp;Véronique Minard ,&nbsp;Isabelle Dumas ,&nbsp;Noura Sellami ,&nbsp;Valentine Martin ,&nbsp;Stéphanie Bolle ,&nbsp;Mario Terlizzi","doi":"10.1016/j.ctro.2025.101104","DOIUrl":"10.1016/j.ctro.2025.101104","url":null,"abstract":"<div><h3>Purpose</h3><div>In pediatric pelvic or perineal rhabdomyosarcoma, organ preservation rates are high following neoadjuvant chemotherapy. We assessed the impact of combining external beam radiation therapy (EBRT) and brachytherapy (BT) on local control and functional outcomes.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed records of all children who received both EBRT and a BT boost in our department from 2005 to 2023. Data collected included tumor relapse, local control, survival and late toxicity rates. Treatment was administered as part of a multimodal conservative radio-surgical approach.</div></div><div><h3>Results</h3><div>Eighteen patients were identified, with a median age of 4 years (range, 2.9 – 8.6 years). According to the Intergroup Rhabdomyosarcoma Study (IRS) risk groups, 10 patients were classified as IRS-III and 8 as IRS-IV. Seven patients had metastases at diagnosis. The median number of chemotherapy cycles prior to local treatment was 8 (range, 5–10). Nine patients (50 %) underwent prior conservative surgery, followed by radiation therapy consisting of both BT and EBRT. This combination was indicated for at least one the following reasons: nodal invasion (n = 11, 61 %), risk of peritoneal dissemination (n = 3, 17 %) and/or local extension (n = 7, 39 %). The median prescribed dose was 20 Gy (range 12–30 Gy) for BT and 50.4 Gy (range, 18.8–55 Gy) for EBRT. Two patients were treated with HDR BT, while the remaining received LDR (n = 4) or PDR (n = 12).The median follow-up period was 4.6 years (range, 2.9–6.6 years). At the last follow-up, failure free-survival was 67 %, local control was 78 % and overall survival was 83 %. Four patients experienced grade II late urinary toxicities, including dysuria or incontinence in two patients. One patient required secondary cystectomy, and another received botulinum toxin injections in the bladder neck.</div></div><div><h3>Conclusion</h3><div>Organ preservation with favorable functional outcome can be achieved in pelvic and perineal rhabdomyosarcoma by combining BT and EBRT, with or without prior surgery. This approach requires close collaboration to develop customized radiation therapy plans. Extended follow-up is necessary to assess long-term functional outcomes.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101104"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the efficacy and immunological impact of combined ICIs and SBRT in HCC: A narrative literature review","authors":"Lara Caglayan ,&nbsp;Oliver Blanck ,&nbsp;Judit Boda-Heggemann ,&nbsp;Thomas Brunner ,&nbsp;Cas Stefaan Dejonckheere ,&nbsp;Dan G. Duda ,&nbsp;Elke Firat ,&nbsp;Maria Hawkins ,&nbsp;Julian Philipp Layer ,&nbsp;Christina Leitzen ,&nbsp;Alejandra Mendez Romero ,&nbsp;Gabriele Niedermann ,&nbsp;Younèss Nour ,&nbsp;Falk Röder ,&nbsp;Gustavo Renato Sarria ,&nbsp;Davide Scafa ,&nbsp;Marta Scorsetti ,&nbsp;Shari Wiegreffe ,&nbsp;Anca-L. Grosu ,&nbsp;Eleni Gkika","doi":"10.1016/j.ctro.2026.101106","DOIUrl":"10.1016/j.ctro.2026.101106","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) represents one of the leading contributors to cancer-related deaths, with the majority of patients diagnosed at stages where curative treatment is no longer possible. Combining stereotactic body radiotherapy (SBRT) with immune checkpoint inhibition (ICI) has gained increasing attention as a therapeutic approach. Beyond its ability to provide high local tumor control (LC), SBRT can provoke immunogenic tumor cell death, promote antigen release and presentation, and modulate the tumor microenvironment in ways that enhance systemic antitumor immunity.</div><div>In this narrative review, we outline the scientific rationale for integrating SBRT with ICIs, discuss mechanistic and translational findings and summarize results from key clinical trials. The currently available data indicate a synergistic interaction, most notably reflected in improved survival and response rates. Nevertheless, variability in dose and fractionation schedules, treatment sequencing, and patient characteristics complicates interpretation. Well-designed prospective studies are needed to establish optimal protocols and identify predictive biomarkers to guide patient selection.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"57 ","pages":"Article 101106"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}